Patrick Lin - 03 Dec 2021 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Role: Chief Business - Strategy Off
Signature: /s/ Patrick Lin by Michael B. Kirwan, as Attorney-in-Fact
Issuer symbol: PCSA
Transactions as of: 03 Dec 2021
Net transactions value: +$16,795
Form type: 4
Filing time: 07 Dec 2021, 15:33:59 UTC
Previous filing: 04 Apr 2022
Next filing: 16 Dec 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PCSA	Common Stock	Purchase	$16,795	+3,500	+0.83%	$4.80	426,390	03 Dec 2021	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.79 to $4.85, inclusive. The Reporting Person undertakes to provide, Processa Pharmaceuticals, Inc. (the "Company") any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

Content

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.79 to $4.85, inclusive. The Reporting Person undertakes to provide, Processa Pharmaceuticals, Inc. (the "Company") any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.